With the advent of highly active anti-retroviral therapy (HAART), significant progress has been achieved in the control of viral replication and prolongation of AIDS-free survival in HIV infected individuals. However, current therapeutic modalities do not effectively target or eliminate latent viral reservoirs. As a result, virus often rebounds after cessation of therapy. Significant side effects and drug-resistance are common due to the necessity for long-term multidrug therapy. An ultimate goal for anti-HIV therapy should therefore be virological eradication, i.e., to cure HIV infection. To date, the feasibility of virologic eradication has only been demonstrated in one HIV-infected patient given an allogeneic hematopoietic cell transplant (HCT) from a CCR5delta32 homozygous donor. Although this is an important proof-of-concept study, the likelihood of using HLA-matched and CCR5delta32 homozygous donor as a general therapeutic approach is remote. The overall objective of this U19 application is to explore strategies to introduce specific modifications in host and proviral DNA to target and eliminate latent HIV reservoir. The goal of this Core is to provide comprehensive support for the proof-of-concept studies in non-human primate models. This goal will be achieved through the execution of the following Specific Aims: (1). To provide animal resources, animal husbandry, and biosafety containment facilities necessary for the study of primate lentivirus infection in a non-human primate model;(2) To provide technical and clinical support for the implementation of non-human primate study protocols in this U19 application;(3) To provide laboratory expertise and analytical support for the monitoring of SHIV infection in macaques;and (4) To provide scientific and administrative oversight for the conduct of non-human primate studies. This Core will interact with all Projects and Cores of this U19.

Public Health Relevance

Despite significant progress has been achieved against HIV/AIDS, a cure remains elusive. Significant side effects and drug-resistance are common due to long-term use of multidrug therapies. A key objective of this U19 application will be to explore strategies to eradicate HIV in infected individuals. The goal of this Core is to provide comprehensive support for the proof-of-concept studies for these strategies in non-human primate models.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI096111-02
Application #
8376033
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$1,019,620
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Peterson, Christopher W; Wang, Jianbin; Norman, Krystin K et al. (2016) Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates. Blood 127:2416-26
Sedlak, Ruth Hall; Liang, Shu; Niyonzima, Nixon et al. (2016) Digital detection of endonuclease mediated gene disruption in the HIV provirus. Sci Rep 6:20064
Dimitrov, Dobromir T; Kiem, Hans-Peter; Jerome, Keith R et al. (2016) A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naïve population. Sci Rep 6:22183
Stone, Daniel; Niyonzima, Nixon; Jerome, Keith R (2016) Genome editing and the next generation of antiviral therapy. Hum Genet 135:1071-82
Spragg, Chelsea; De Silva Feelixge, Harshana; Jerome, Keith R (2016) Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS 11:442-9
Romano Ibarra, Guillermo S; Paul, Biswajit; Sather, Blythe D et al. (2016) Efficient Modification of the CCR5 Locus in Primary Human T Cells With megaTAL Nuclease Establishes HIV-1 Resistance. Mol Ther Nucleic Acids 5:e352
Johnston, Christine; Harrington, Robert; Jain, Rupali et al. (2016) Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant 22:149-56
De Silva Feelixge, Harshana S; Stone, Daniel; Pietz, Harlan L et al. (2016) Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res 126:90-8
Peterson, Christopher W; Haworth, Kevin G; Burke, Bryan P et al. (2016) Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. Mol Ther Methods Clin Dev 3:16007
Adair, Jennifer E; Waters, Timothy; Haworth, Kevin G et al. (2016) Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun 7:13173

Showing the most recent 10 out of 44 publications